Which companies are TaiMed Biologics's closest peers?

The cockpit's peer set: Steminent Biotherapeutics (7729.TWO), Qingdao Vland Biotech (603739.SS), Komipharm International (041960.KS), Shanghai Obio Technology (Group) (688238.SS), Shattuck Labs (STTK), Shanghai Shen Lian Biomedical (688098.SS), Wuhan Hiteck Biological Pharma (300683.SZ), Eupraxia Pharmaceuticals (EPRX.TO).

How has TaiMed Biologics stock performed?

Over six months to 6 Nov 2026 the shares returned +10.4% against -7.3% for the median peer; over one year -24.6%.

← CockpitCompetitor Analysis › 4147.TWO TaiMed Biologics Inc.Open in the cockpit ↗

TaiMed Biologics Inc.4147.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Momentum strong 74

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$454M

US dollars, full cap

Free float

77%

of shares outstanding

$/day

$1.30M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-10.9 pp

WACC 5.0%

Hurdle

+35 pp

Req g minus delivered

Next earnings

12 days

18 Nov 2026

Close · TWDNT$55.00

1D-0.2%

1W-4.2%

1M-8.3%

3M-4.5%

6M+10.4%

YTD-10.1%

1Y-24.6%

ATR %4.2%

52w lowhigh28.4% off high

What TaiMed Biologics does

No business profile yet.

TaiMed Biologics at a glance

Size TaiMed Biologics (4147.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $454M, the 476th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$55.00 on 6 Nov 2026.

Performance Over six months the shares gained 10.4%, against -7.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 3.6% over the last twelve months (peer median +5.4%); the operating margin is -30.3% (peer median -9.8%).

Valuation It trades at 22.4× enterprise value to sales against a peer median of 10.7× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 10.9 points below its cost of capital (5.0% WACC).

Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: TaiMed Biologics against the median of its 20 peers (local-currency closes).

TaiMed Biologics financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	NT$619M	NT$611M	NT$610M	NT$492M	NT$563M
Revenue growth	—	0%	+24%	-13%	—
Gross profit	NT$228M	NT$203M	NT$155M	NT$168M	NT$154M
EBITDA	-NT$34.3M	-NT$41.7M	-NT$98.6M	-NT$11.5M	-NT$36.0M
Net income	-NT$139M	-NT$168M	-NT$202M	-NT$195M	-NT$269M
Free cash flow	NT$108M	NT$168M	-NT$388M	-NT$31.8M	-NT$609M
Capital expenditure	NT$47.2M	NT$22.8M	NT$19.4M	NT$6.15M	NT$4.76M
Total debt	NT$478M	NT$493M	NT$523M	NT$751M	NT$766M

Quarterly statements and history in the cockpit →

TaiMed Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. TaiMed Biologics is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TaiMed Biologics is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TaiMed Biologics is the large dot.

TaiMed Biologics competitors and peer comparison

How TaiMed Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TaiMed Biologics against its 20 peers (data as of 6 Nov 2026)
Measure	4147.TWO	Peer median	Rank in peer set
1-month return	-8.3%	-13.9%	6th highest of 21
6-month return	+10.4%	-7.3%	4th highest of 20
Distance from 52-week high	-28.4%	-35.3%	7th highest of 21
Revenue growth (TTM)	+3.6%	+5.4%	8th lowest of 16
Operating margin	-30.3%	-9.8%	6th lowest of 16
EV / Sales	22.4×	10.7×	3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)	31.8%	10.6%	2nd most demanding of 7
Growth delivered (Del g)	-3.3%	+3.9%	3rd lowest of 7
Hurdle (Req g minus delivered)	+35.1 pp	+15.2 pp	2nd most demanding of 7
ROIC minus cost of capital	-10.9 pp	-9.3 pp	8th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
TaiMed Biologics 4147.TWO	Taiwan	$454M	+10%	+4%	-30%	22.4×	31.8%	-3.3%
Steminent Biotherapeutics 7729.TWO	Taiwan	$458M	+139%	n/a	n/a	n/a	n/a	n/a
Qingdao Vland Biotech 603739.SS	China	$450M	-21%	+5%	7%	2.3×	18.2%	+7.3%
Komipharm International 041960.KS	South Korea	$460M	-12%	-3%	2%	12.1×	n/a	n/a
Shanghai Obio Technology (Group) 688238.SS	China	$462M	-4%	+20%	-79%	11.4×	n/a	n/a
Shattuck Labs STTK	United States	$464M	-33%	-67%	-5,571%	258.1×	n/a	n/a
Shanghai Shen Lian Biomedical 688098.SS	China	$444M	-18%	-17%	-16%	12.1×	n/a	n/a
Wuhan Hiteck Biological Pharma 300683.SZ	China	$443M	-36%	-30%	-27%	5.9×	n/a	n/a
Eupraxia Pharmaceuticals EPRX.TO	Canada	$466M	-5%	n/a	n/a	n/a	n/a	n/a
Medigen Vaccine Biologics 6547.TWO	Taiwan	$467M	-5%	+44%	10%	18.0×	n/a	n/a
Jacobio Pharmaceuticals 1167.HK	Hong Kong	$468M	-27%	+286%	68%	2.5×	-14.9%	-36.1%
Shanghai ZJ Bio-Tech 688317.SS	China	$468M	-16%	-18%	-75%	5.2×	6.0%	-62.3%
TenNor Therapeutics Suzhou 6872.HK	Hong Kong	$440M	n/a	n/a	n/a	n/a	n/a	n/a
Hanx Biopharmaceuticals (Wuhan) 3378.HK	Hong Kong	$469M	-13%	n/a	n/a	n/a	n/a	n/a
Ever Supreme Bio Technology 6712.TWO	Taiwan	$439M	+9%	+13%	47%	12.7×	5.8%	+70.5%
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	8,168.1×	n/a	n/a
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%
Hubei Goto Biopharm 300966.SZ	China	$427M	-7%	+6%	-10%	6.4×	n/a	n/a
EirGenix 6589.TW	Taiwan	$427M	+2%	+27%	-71%	10.7×	n/a	n/a
Polynovo PNV.AX	Australia	$426M	-12%	+13%	5%	4.2×	53.3%	+37.6%

Questions

Which companies are TaiMed Biologics's closest peers?: The cockpit's peer set: Steminent Biotherapeutics (7729.TWO), Qingdao Vland Biotech (603739.SS), Komipharm International (041960.KS), Shanghai Obio Technology (Group) (688238.SS), Shattuck Labs (STTK), Shanghai Shen Lian Biomedical (688098.SS), Wuhan Hiteck Biological Pharma (300683.SZ), Eupraxia Pharmaceuticals (EPRX.TO).
Is TaiMed Biologics expensive compared with its peers?: On ev / sales it trades at 22.4× against a peer median of 10.7×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has TaiMed Biologics stock performed?: Over six months to 6 Nov 2026 the shares returned +10.4% against -7.3% for the median peer; over one year -24.6%.